BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Badri P, Jiang X, Borodovsky A, Najafian N, Kim J, Clausen VA, Goel V, Habtemariam B, Robbie GJ. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet 2021;60:365-78. [PMID: 33047216 DOI: 10.1007/s40262-020-00940-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Qi R, Qin W. Role of Complement System in Kidney Transplantation: Stepping From Animal Models to Clinical Application. Front Immunol 2022;13:811696. [PMID: 35281019 DOI: 10.3389/fimmu.2022.811696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yamada Y. Nucleic Acid Drugs-Current Status, Issues, and Expectations for Exosomes. Cancers (Basel) 2021;13:5002. [PMID: 34638486 DOI: 10.3390/cancers13195002] [Reference Citation Analysis]
3 Jalink M, de Boer ECW, Evers D, Havinga MQ, Vos JMI, Zeerleder S, de Haas M, Jongerius I. Halting targeted and collateral damage to red blood cells by the complement system. Semin Immunopathol 2021. [PMID: 34191092 DOI: 10.1007/s00281-021-00859-8] [Reference Citation Analysis]
4 Chen Y, Chu JMT, Chang RCC, Wong GTC. The Complement System in the Central Nervous System: From Neurodevelopment to Neurodegeneration. Biomolecules 2022;12:337. [PMID: 35204837 DOI: 10.3390/biom12020337] [Reference Citation Analysis]
5 Rana S, Bhatnagar A, Singh S, Prabhakar N. Evaluation of liver specific ionizable lipid nanocarrierin the delivery of siRNA. Chem Phys Lipids 2022;:105207. [PMID: 35623403 DOI: 10.1016/j.chemphyslip.2022.105207] [Reference Citation Analysis]
6 Kulasekararaj AG, Brodsky RA, Nishimura JI, Patriquin CJ, Schrezenmeier H. The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol 2022;13:20406207221091046. [PMID: 35663504 DOI: 10.1177/20406207221091046] [Reference Citation Analysis]
7 McCombe JA, Pittock SJ. Anti-complement Agents for Autoimmune Neurological Disease. Neurotherapeutics 2022. [PMID: 35553024 DOI: 10.1007/s13311-022-01223-w] [Reference Citation Analysis]
8 Jia C, Tan Y, Zhao M. The complement system and autoimmune diseases. Chronic Diseases and Translational Medicine. [DOI: 10.1002/cdt3.24] [Reference Citation Analysis]
9 Fan Y, Yang Z. Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application. Pharmaceutics 2022;14:1193. [DOI: 10.3390/pharmaceutics14061193] [Reference Citation Analysis]
10 Fernandez-ruiz R, Belmont HM. The role of anti-complement therapy in lupus nephritis. Translational Research 2022. [DOI: 10.1016/j.trsl.2022.02.001] [Reference Citation Analysis]